Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
Add to My Watchlist
Price and Volume
N/A - N/A
N/A - N/A
RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy
June 13, 2017
Research Conducted Under Material Transfer Agreement Provides Potential Therapeutic Target for RGN-352
RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017
May 09, 2017
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its joint...
RegeneRx Releases Annual Letter to Shareholders
March 13, 2017
RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
February 27, 2017
RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.
January 09, 2017
RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4
December 16, 2016
RegeneRx to Present at 9th Annual LD Micro Investor Conference
November 30, 2016
RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259
November 09, 2016
RegeneRx Receives Notice of Allowance for Patent for T?4 Eye Drop Formulation
November 02, 2016
RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome
September 30, 2016
RegeneRX Biopharmaceuticals, Inc. (RGRX) Helping Patients with Multiple Sclerosis
February 06, 2017
Stock Market JSON API
provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial